Brief: Enlivex Receives Notice Of Allowance For U.S. Patent Application Covering The Use Of Allocetra™ To Prevent Cytokine Release Syndrome In Patients Receiving Car T Cell Therapy
06/09/2022 13:22
Sept 6 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX RECEIVES NOTICE OF ALLOWANCE FOR U.S. PATENT
APPLICATION
COVERING THE USE OF ALLOCETRA™ TO PREVENT CYTOKINE RELEASE
SYNDROME IN PATIENTS RECEIVING CAR T CELL THERAPY
Source text for Eikon: ID:nGNX1nxdfz
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment